Results 251 to 260 of about 10,652,159 (339)

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Applications of artificial intelligence in drug discovery for neurological diseases. [PDF]

Neurotherapeutics
Ekins S, Lane TR.
europepmc   +1 more source

Butylphthalide reduces plaque burden and improves neurological function in carotid atherosclerotic disease: a pooled analysis

Jia Yang, Xinhao Pei, Judy Qiang, Lijuan Li, Yanping Liu, Panpan Hao   +5 more
openalex   +1 more source

SNUPN‐Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SNUPN‐related muscular dystrophy or LGMDR29 is a new entity that covers from a congenital or childhood onset pure muscular dystrophy to more complex phenotypes combining neurodevelopmental features, cataracts, or spinocerebellar ataxia. So far, 12 different variants have been described.
Nuria Muelas, Pablo Iruzubieta, Alberto Damborenea, Laura Pérez‐Fernández, Inmaculada Azorín, Juan Carlos Jiménez García, Ana Töpf, Pilar Martí, Lorena Fores‐Toribio, María Manterola, Rosana Blanco‐Mañez, Oihane Pikatza‐Menoio, Sonia Alonso‐Martín, Volker Straub, Aitziber L. Cortajarena, Adolfo López de Munain, David De Sancho, Lorea Blázquez, Juan J. Vilchez   +18 more
wiley   +1 more source

Activity and Heterogeneity of Astrocytes in Neurological Diseases: Molecular Mechanisms and Therapeutic Targets. [PDF]

MedComm (2020)
Mao S, Qiao R, Wang Q, Shen L, Li D, Huo X, Wang J, Liu K, Chen W, Zhu T, Zhang B, Leng S, Bai Y.   +12 more
europepmc   +1 more source

Psychiatric Manifestations of Neurological Diseases: A Narrative Review

Anthony Maristany, C Brianna, Cameron Murray, Ashwin Subramaniam, Sean E. Oldak   +4 more
openalex   +1 more source

HIV/AIDS and neurologic diseases [PDF]

, 2010
Steven Karceski
openalex   +1 more source

Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations [PDF]

, 2016
et al,, Urano, Fumihiko
core   +1 more source

Relapsing–Remitting Multiple Sclerosis Is Associated With a Dysbiotic Oral Microbiome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and neurological impairment. While the gut microbiota's role in MS is extensively studied, the association between the oral microbiota and MS remains underexplored, particularly in North American cohorts.
Sukirth M. Ganesan, Meeta Yadav, Sudeep Ghimire, Peter C. Lehman, Apurva J. Patel, Sydney Woods, Heena Olalde, Jemmie Hoang, Mishelle Paullus, Catherine Cherwin, Christine Gill, Tracey Cho, Ashutosh K. Mangalam   +12 more
wiley   +1 more source

Patients Presented With Common Neurological Diseases Admitted to Referral Neuroscience Hospital in Bangladesh. [PDF]

Cureus
Dola T, Mamun AA, Siddika S, Yusuf MA.
europepmc   +1 more source